A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Servier
Servier
Neonc Technologies, Inc.
Qurient Co., Ltd.
Essen Biotech
Nouscom SRL
Takeda
Linnaeus Therapeutics, Inc.
Inhibrx Biosciences, Inc
NuCana plc
Medicenna Therapeutics, Inc.
Mayo Clinic
Aprea Therapeutics
MacroGenics
Merus B.V.
NextCure, Inc.
Celularity Incorporated
Essen Biotech
NGM Biopharmaceuticals, Inc
Mural Oncology, Inc
Kineta Inc.
Incyte Corporation
Incyte Corporation
Western Regional Medical Center